Update on vasculitis - 15/08/11
Reprint requests: Carol A. Langford, MD, MHS, Cleveland Clinic, 9500 Euclid Ave, A50, Cleveland, OH 44195.Abstract |
The primary systemic vasculitides comprise a broad group of diseases identified by their clinical, histopathologic, and therapeutic characteristics. These unique entities have a broad spectrum of organ involvement and severity, which influences the approach to diagnosis and treatment. Immunosuppressive and cytotoxic agents are used to manage most vasculitic diseases. Long-term outcome is influenced by chronic sequelae from organ damage, disease relapses, and medication side effects. Further research is needed to understand these diseases and discover more efficacious yet less toxic therapeutic options. This review will focus on vasculitic syndromes more likely to be presented to an allergist/immunologist in an outpatient setting.
Le texte complet de cet article est disponible en PDF.Key words : Vasculitis, antineutrophil cytoplasmic antibodies, diagnosis, treatment
Abbreviations used : ANCA, AZA, cANCA, CSS, CV, CYC, EIA, GCA, HSP, HUVS, IIF, IVIG, KD, LTA, MPA, MPO, MTX, PAN, pANCA, PR3, TAB, TAK, TMP-SMZ, UV, WG
Plan
| Disclosure of potential conflict of interest: C. A. Langford receives research support from Genentech and Bristol-Myers Squibb and serves on the professional meetings subcommittee and the continuous professional development subcommittee for the American College of Rheumatology. A. Khasnis has declared that he has no conflict of interest. |
Vol 123 - N° 6
P. 1226-1236 - juin 2009 Retour au numéro
Article précédent
- Rural health disparities in asthma care and outcomes
- Robert S. Valet, Tamara T. Perry, Tina V. Hartert
- Eliminating health disparities: What have we done and what do we do next?
- Andrea J. Apter, Adrian M. Casillas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?